Shoaib Akhtar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shoaib Akhtar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Asim Elahi
Harlingen Medical Center
1 shared publication Aziz Ur Rehman
Department of Pulmonology, Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan
1 shared publicationHabib Rehman
Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
1 shared publicationJaved Iqbal
Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
1 shared publication- Mazhar Hussain
Department of Pharmacology, Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan
1 shared publication Muhammad Bilal Ghafoor
Pathology, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by Medeye Publishers in Biological and Clinical Sciences Research Journal
- Vol. 6 (6) , 49-52
Frequency of Errors in Inhaler Technique among Patients Using Metered-Dose Inhalers (MDIs) in a Tertiary Care Hospital
Proper use of metered-dose inhalers (MDIs) is essential for optimal drug delivery and management of respiratory conditions such as asthma and COPD. However, incorrect inhaler technique remains a common issue, particularly among patients who do not use spacer devices. Identifying and addressing these errors is crucial to ensure therapeutic efficacy. Objective: This study aims to assess the frequency of errors in inhaler technique among patients using metered-dose inhalers (MDIs) without spacer devices in a tertiary care hospital. Methods: This cross-sectional study was conducted at the Department of Pulmonology, Sheikh Zayed Hospital, Rahim Yar Khan, from November 30, 2020, to May 29, 2021. A total of 96 patients aged 15 to 65 years who used MDIs without spacers for more than three months were included. Patients with physical limitations, newly diagnosed cases, and those using spacers were excluded. Inhaler technique was assessed using a standardised checklist based on handling and inhalational errors, including steps such as shaking the inhaler, maintaining an upright posture, and proper breathing coordination. Results: The mean age of participants was 40.13 ± 7.77 years, with 59.4% males and 40.6% females. Errors in inhaler technique were observed in 39 (40.6%) patients. Handling errors were more common (22.9%) than inhalational errors (17.7%). Common errors included failure to exhale fully before inhalation (6.3%) and not holding breath for at least 10 seconds after inhalation (6.3%). Conclusion: The frequency of errors in inhaler technique among MDI users is high, emphasising the need for patient education and structured training programs to improve inhaler use and disease management outcomes.
- 30 June 2025
- Published by Medeye Publishers in Biological and Clinical Sciences Research Journal
- Vol. 6 (6) , 49-52
Open AccessFrequency of Errors in Inhaler Technique among Patients Using Metered-Dose Inhalers (MDIs) in a Tertiary Care Hospital
Proper use of metered-dose inhalers (MDIs) is essential for optimal drug delivery and management of respiratory conditions such as asthma and COPD. However, incorrect inhaler technique remains a common issue, particularly among patients who do not use spacer devices. Identifying and addressing these errors is crucial to ensure therapeutic efficacy. Objective: This study aims to assess the frequency of errors in inhaler technique among patients using metered-dose inhalers (MDIs) without spacer devices in a tertiary care hospital. Methods: This cross-sectional study was conducted at the Department of Pulmonology, Sheikh Zayed Hospital, Rahim Yar Khan, from November 30, 2020, to May 29, 2021. A total of 96 patients aged 15 to 65 years who used MDIs without spacers for more than three months were included. Patients with physical limitations, newly diagnosed cases, and those using spacers were excluded. Inhaler technique was assessed using a standardised checklist based on handling and inhalational errors, including steps such as shaking the inhaler, maintaining an upright posture, and proper breathing coordination. Results: The mean age of participants was 40.13 ± 7.77 years, with 59.4% males and 40.6% females. Errors in inhaler technique were observed in 39 (40.6%) patients. Handling errors were more common (22.9%) than inhalational errors (17.7%). Common errors included failure to exhale fully before inhalation (6.3%) and not holding breath for at least 10 seconds after inhalation (6.3%). Conclusion: The frequency of errors in inhaler technique among MDI users is high, emphasising the need for patient education and structured training programs to improve inhaler use and disease management outcomes.
- Open Access
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
Background Type 2 diabetes is a chronic metabolic disorder that is escalating at an alarming rate worldwide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are recent oral antihyperglycemic drugs (OADs) with a unique mechanism of action. Objectives This study aimed compared the efficacy and safety profiles of two SGLT-2 inhibitors, empagliflozin and dapagliflozin, in patients with type 2 diabetes as add-on therapy to traditional first-line OADs. Methods We conducted a randomized controlled trial comparing empagliflozin and dapagliflozin in patients with type 2 diabetes. Patients were included in the study if they had type 2 diabetes with inadequate glycemic control, defined as glycated hemoglobin (HbA1c) of 7.5% to 11.0%, treated with conventional first-line OADs. Study participants were randomly assigned into two groups. Group A patients received oral empagliflozin, 10 to 25 mg, and Group B patients received oral dapagliflozin, 5 to 10 mg, for 12 weeks. The primary endpoint was the efficacy profile for each SGLT-2 agent in terms of body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c. The secondary endpoint was to determine the safety and tolerability profiles of each SGLT-2 agent. Results After 12 weeks of treatment, the mean body weight was reduced significantly in both groups from baseline (empagliflozin: -3.2 kg ± 5.5 kg, p = 0.003; dapagliflozin -2.1 kg ± 4.6 kg, p = 0.008). However, the mean body weight reduction between groups was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m2 to 25.8 ± 5.2 kg/m2, p = 0.002; dapagliflozin from 29 ± 5.2 kg/m2 to 27.7 ± 4.8 kg/m2, p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007). The mean FBG was also reduced in both study groups (empagliflozin: -88.5 mg/dL ± 39.7 mg/dl, p = 0.003; dapagliflozin: -59.8 mg/dL ± 48.5 mg/dL; p = 0.007). However, the patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001). HbA1c was also significantly reduced in both groups (empagliflozin: -2.1% ± 1.1%, p = 0.002; dapagliflozin: -1.4% ± 0.9%; p = 0.004). However, patients who received empagliflozin experienced a significantly greater reduction in HbA1c than patients who received dapagliflozin (p = 0.001). The tolerability profiles of both SGLT-2 agents were quite good, and no major adverse effects were reported in the study groups. Urinary infection occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001). Conclusion Both empagliflozin and dapagliflozin demonstrated excellent efficacy and safety profiles in our study. These agents should be considered as add-on therapy in patients with type 2 diabetes taking conventional first-line OADs.
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Open AccessComparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
Background Type 2 diabetes is a chronic metabolic disorder that is escalating at an alarming rate worldwide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are recent oral antihyperglycemic drugs (OADs) with a unique mechanism of action. Objectives This study aimed compared the efficacy and safety profiles of two SGLT-2 inhibitors, empagliflozin and dapagliflozin, in patients with type 2 diabetes as add-on therapy to traditional first-line OADs. Methods We conducted a randomized controlled trial comparing empagliflozin and dapagliflozin in patients with type 2 diabetes. Patients were included in the study if they had type 2 diabetes with inadequate glycemic control, defined as glycated hemoglobin (HbA1c) of 7.5% to 11.0%, treated with conventional first-line OADs. Study participants were randomly assigned into two groups. Group A patients received oral empagliflozin, 10 to 25 mg, and Group B patients received oral dapagliflozin, 5 to 10 mg, for 12 weeks. The primary endpoint was the efficacy profile for each SGLT-2 agent in terms of body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c. The secondary endpoint was to determine the safety and tolerability profiles of each SGLT-2 agent. Results After 12 weeks of treatment, the mean body weight was reduced significantly in both groups from baseline (empagliflozin: -3.2 kg ± 5.5 kg, p = 0.003; dapagliflozin -2.1 kg ± 4.6 kg, p = 0.008). However, the mean body weight reduction between groups was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m2 to 25.8 ± 5.2 kg/m2, p = 0.002; dapagliflozin from 29 ± 5.2 kg/m2 to 27.7 ± 4.8 kg/m2, p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007). The mean FBG was also reduced in both study groups (empagliflozin: -88.5 mg/dL ± 39.7 mg/dl, p = 0.003; dapagliflozin: -59.8 mg/dL ± 48.5 mg/dL; p = 0.007). However, the patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001). HbA1c was also significantly reduced in both groups (empagliflozin: -2.1% ± 1.1%, p = 0.002; dapagliflozin: -1.4% ± 0.9%; p = 0.004). However, patients who received empagliflozin experienced a significantly greater reduction in HbA1c than patients who received dapagliflozin (p = 0.001). The tolerability profiles of both SGLT-2 agents were quite good, and no major adverse effects were reported in the study groups. Urinary infection occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001). Conclusion Both empagliflozin and dapagliflozin demonstrated excellent efficacy and safety profiles in our study. These agents should be considered as add-on therapy in patients with type 2 diabetes taking conventional first-line OADs.